Oncolytic viral therapy as promising immunotherapy against glioma

• DOI: 10.1002/mef2.61
• Publication Date: 2023-10-17T04:19:59Z
• Authors: Die Hu; Yaomei Tian; Jie Xu; Daoyuan Xie; Yusi Wang; Mohan Liu; Yuanda Wang; Li Yang
• Keywords: Chemoradiotherapy; Immune checkpoint; Brain tumor

Abstract Glioma is a common primary central nervous system malignant tumor in clinical, traditional methods such as surgery and chemoradiotherapy are not effective treatment. Therefore, more treatments need to be found. Oncolytic viruses (OVs) new type of immunotherapy that selectively infects kills cells instead normal cells. OVs can mediate antitumor immune responses through variety mechanisms, have the ability activate responses, transform microenvironment from “cold” “hot,” enhance efficacy checkpoint inhibitors. Recently, large number preclinical clinical studies shown show great prospects treatment gliomas. In this review, we summarize current status glioma therapies with focus on OVs. First, article introduces their respective shortcomings. Then, important progress trials summarized. Finally, urgent challenges oncolytic virus for sorted out, related solutions proposed. This review will help further promote use glioma.